|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Medical genetics: a marker for Stevens-Johnson syndrome.
|
15057820 |
2004 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our data suggest that HLA-B*1502 could contribute to the pathogenesis of CBZ-SJS/TEN, and that genetic susceptibility to CBZ-induced cADRs is phenotype-specific.
|
16538176 |
2006 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Our data suggest that HLA-B*1502 could contribute to the pathogenesis of CBZ-SJS/TEN, and that genetic susceptibility to CBZ-induced cADRs is phenotype-specific.
|
16538176 |
2006 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Studies have reported an association of HLA-B*1502 and HLA-B*5801 in patients with the Stevens-Johnson syndrome or toxic epidermal necrolysis provoked by carbamazepine, as well as of HLA-B*5701 with abacavir hypersensitivity.
|
18991696 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.
|
18855540 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B genotyping was performed on 150 patients included in a European study (RegiSCAR) of SJS and TEN.
|
18192896 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*5901 exhibited a high odds ratio for SJS/TEN with ocular complications.
|
18385790 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
While HLA-B*1502 is unlikely to be associated with carbamazepine-related or aromatic anti-epileptic agent-related SJS/TEN, HLA-B*5801 was significantly associated with allopurinol-related SJS/TEN in Japanese.
|
19018717 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.
|
18855540 |
2008 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The sensitivity and specificity of the HLA-B*5801 allele for prediction of allopurinol-induced SJS/TEN were 100 and 87%, respectively.
|
19696695 |
2009 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This has led to the recommendation that patients of Asian ancestry be tested for the HLA-B*1502 allele, in order to identify those at high risk of developing Stevens-Johnson syndrome and toxic epidermal necrolysis after administration of carbamazepine and, possibly, phenytoin and other antiepileptic drugs.
|
19262378 |
2009 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition to CBZ, HLA-B*5801 was also found to associate with allopurinol-induced TEN/SJS.
|
20536296 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Available data also suggest that HLA-B*1502 is a risk allele for SJS/TEN caused by other aromatic AEDs with a similar structure to CBZ.
|
20001755 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We first identified that HLA-B*1502 is strongly associated with carbamazepine (CBZ)-induced SJS/TEN and HLA-B*5801 with allopurinol-SJS/TEN in Han Chinese.
|
20962567 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our data suggest that HLA-B*1511, a member of HLA-B75, is a risk factor for carbamazepine-induced SJS/TEN in Japanese.
|
21204807 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Results from this study suggest that HLA-B*1502 may be a useful pharmacogenetic test for screening Thai individuals who may be at risk for CBZ-induced SJS and TEN.
|
20345939 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Genetic and ethnic risk factors associated with drug hypersensitivity.
|
20485159 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Genetic susceptibility to SJS and TEN is likely as exemplified by the strong association observed in Han Chinese between a genetic marker, the human leukocyte antigen HLA-B*1502, and SJS induced by carbamazepine.
|
21162721 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*5901 may be a useful screening marker for predicting methazolamide-induced SJS/TEN in patients of Korean and Japanese ancestry.
|
20504258 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians.
|
19915237 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
CTD_human |
In addition, HLA-B*1301, Cw*0801 and DRB1*1602 also showed an association with PHT-SJS/TEN (p = 0.0128-0.0281; OR: 3.0-4.3).
|
20235791 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
CTD_human |
HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions.
|
19694795 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We found that HLA-B*1502 was present in eight out of 26 (30.8%) PHT-SJS/TEN (OR: 5.1; 95% CI: 1.8-15.1; p = 0.0041), two out of six (33%) LTG-SJS (odds ratio [OR]: 5.1; 95% CI: 0.8-33.8; p = 0.1266) and three out of three (100%) OXC-SJS (OR: 80.7; 95% CI: 3.8-1714.4; p = 8.4 x 10(-4)) patients.
|
20235791 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*1502 genotyping with sequence-specific primer polymerase chain reaction (PCR-SSP) and PCR-sequencing based typing (PCR-SBT) was performed on 17 CBZ-induced SJS/TEN patients, 21 CBZ-tolerant controls, and 185 healthy controls recruited during 2008-2010.
|
21424386 |
2011 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported that patients with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (PHT-induced SJS/TEN) were positive for HLA-B*1502.
|
21216202 |
2011 |